If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||
![]() CephalalgiaVolume 9 Issue 4, Pages 287 - 291 Published Online: 19 Jan 2002 © 2009 International Headache Society Published on behalf of the International Headache Society
Abstract | Full Text: PDF (Size: 33K) | Related Articles | Citation Tracking The dose of propranolol for migraine prophylaxis. Efficacy of low doses Copyright International Headache Society KEYWORDS Migraine • migraine prophylaxis • propranolol ABSTRACTAlthough propranolol is still the drug of first choice for migraine prophylaxis, the optimal antimigraine dose of this drug is still unknown. The main aim of our study is to clarify this point. Fifty-three patients suffering from severe migraine attacks were given propranolol at low doses, close to or up to 1 mgkg body weight daily, for one month. If the patient responded, then treatment was maintained unchanged for a further two months. If the patient did not respond, propranolol was progressively increased until control was obtained. Thirty-nine (73.5%) patients responded to low doses, and 7 of the 17 patients whose dose had been increased, because of poor or absent response, showed improvement. Five patients did not finish the study because of intolerable side effects, which intensified as the dose was increased. Tolerance was not noticed. In addition to confirming the well-known utility of propranolol in migraine prophylaxis, our results show that low doses are effective in controlling serious migraine bouts in many patients. Fewer than a third of patients will need higher doses in controlling migraine attacks. Accepted 20 July 1989 |